Adjuvant Tamoxifen for male breast cancer (MBC)

Ribeiro, G; Swindell, Ric

doi:10.1038/bjc.1992.50

Cited by 168 publications

(98 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, however, limited information is available on the toxicities of these agents in the setting of male breast cancer. Early studies evaluating the efficacy of tamoxifen in male breast cancer reported few side effects to tamoxifen 23,24 . A later article reported 2 cases of impotence secondary to tamoxifen treatment 25 , but to our knowledge, only one study of tamoxifen toxicity in male breast cancer has been published 26 .…”

Section: Resultsmentioning

confidence: 99%

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

Purpose: Most male breast cancer tumours are hormone receptor–positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endocrine therapy. In the present study, we examined rates of adherence to and toxicity from endocrine treatments in male breast cancer patients treated at a single institution. Patients and Methods: We conducted a retrospective study of male patients diagnosed with breast cancer at The Ottawa Hospital Cancer Centre during 1981–2003. Data collected included patient age, hormone receptor status, therapy adherence, self-reported toxicities, and type and duration of endocrine therapies. Results: The review located 59 cases of early-stage and metastatic male breast cancer. Median patient age was 68.0 years. Tamoxifen was given to 38 patients (64.4%), anastrozole to 8 (13.6%), and letrozole to 5 (8.5%). Of patients who received endocrine therapy, 10 (25%) received adjuvant systemic chemotherapy. Toxicity was reported by 19 patients taking tamoxifen (50%), with hot flashes being the most common complaint (18.4%). Decreased libido, weight gain, and malaise were reported by 5 patients (13.2%). Rash and erectile dysfunction were reported by 3 patients (7.9%). Increased liver enzymes, pulmonary embolism, superficial thrombophlebitis, myalgia, depression, visual blurring, and loose stools were each reported in 1 patient (2.6%). Tamoxifen therapy was discontinued secondary to toxicity in 9 patients (23.7%). Of the patients treated with anastrozole, 3 (37.5%) reported toxicity, with 1 report each of decreased libido, leg swelling, and depression (12.5%). Toxicity was reported in 2 patients taking letrozole (40%), with both reporting peripheral edema, and 1 reporting hot flashes. No patient discontinued anastrozole or letrozole because of toxicity. Conclusions: Few studies specifically report data on adherence to and toxicities from endocrine therapies in male breast cancer patients. The rate of discontinuation at our institution because of toxicity (23.7%) is similar to that reported in the female breast cancer population. Future prospective studies should explore strategies to improve adherence to endocrine therapy in this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

show abstract

“…Evidence-based guidelines for adjuvant systemic therapy in FBC are rapidly implemented into community practice (30), but the same may not be true for MBC. The smaller improvement for male hazard ratios suggests a delay and/or underutilization of adjuvant therapy in males compared to females, in particular tamoxifen for hormone-positive MBC (31). Use of tamoxifen for MBC may also be limited by poor compliance due to its association with a high rate of treatment-limiting side effects in males (32), including decreased libido, weight gain, hot flashes and deep vein thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Male breast cancer: A retrospective study comparing survival with female breast cancer

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract.Male breast cancer is a rare disease. The aim of this study was to compare overall survival (OS) and disease-free survival (DFS) in a group of matched males and females with breast cancer. The clinical data and survival status of 42 operable male breast cancer (MBC) cases treated at the Central Hospital of Tai'an from 1982 to 2006 were collected. Each MBC patient recorded in the database was matched with two female breast cancer (FBC) patients. Matching was conducted based on age, year of diagnosis, stage and pathology. SPSS 16.0 software was used for statistical analysis. The Chi-square test was used for the categorical data, the Kaplan-Meier method was applied to analyze survival and the log-rank test was used to compare curves between the groups. P<0.05 was considered to indicate a statistically significant difference. The 42 MBC patients were matched with 84 FBC patients. The mean age at diagnosis was 58.0±11.3 years for males and 57.1±10.6 years for females, and the median follow-up time was 64 months (range, 5-262 months) for males and 71 months (range, 29-283 months) for females. Significant differences were identified for tumor location, hormone receptor status, adjuvant chemotherapy and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node status and AJCC stage were prognostic factors in MBC patients. The 5-and 10-year DFS rates were 61.2 and 40.7% for males, and 68.7 and 43.0% for females, respectively. The 5-and 10-year OS rates were 75.3 and 52.3% for males, and 82.9 and 63.2% for females, respectively. In our study, male breast carcinoma patients had a worse prognosis compared to female breast carcinoma patients which may be due to the deficiency of adjuvant chemotherapy and endocrine therapy.

show abstract

“…Standard of hormone therapy in the first line is antiestrogene Tamoxifen (Ribeiro and Swindell, 1992). Clinical investigations show that the benefit of Tamoxifen therapy can also be achieved with the receptor negative tumors, but to a lesser extent, and that most possibly originates from the response of those patients whose receptors are negative, but present.…”

Section: Multivariate Analysis Of Prognostic Factors In Male Breast Cmentioning

confidence: 99%

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Šipetić-Grujičić

Murtezani²,

Z³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was 64.3±10.5 years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ≤2 cm, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.

show abstract

Adjuvant Tamoxifen for male breast cancer (MBC)

Cited by 168 publications

References 11 publications

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

Male breast cancer: A retrospective study comparing survival with female breast cancer

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Contact Info

Product

Resources

About